Cure8 research brief
Adding a mesalazine retention enema to oral mesalazine improved short-term symptom relief and endoscopic signs of mucosal healing in mild-to-moderate left-sided ulcerative colitis in this retrospective study. That could matter for people with E2 (left-sided) disease seeking faster symptom control.
Adults with left-sided (E2) ulcerative colitis, gastroenterologists and IBD clinicians, and researchers studying topical plus oral 5-ASA strategies.
This retrospective cohort study compared oral mesalazine enteric-coated tablets alone to the same oral regimen plus a daily mesalazine retention enema in adults with mild-to-moderate left-sided (E2) active ulcerative colitis over 30 days.
The combination group showed higher short-term clinical response and faster symptom improvement, and lower endoscopic subscores and mucosal inflammation at follow-up; adverse events were mild and similar between groups. The paper reports real-world, single-center, retrospective data with a small sample (88 patients) and a short treatment period (30 days).
These features make the results encouraging but preliminary; the authors call for larger prospective studies with longer follow-up to confirm durability and safety.
If you are a patient considering topical therapy, this study supports that adding a mesalazine enema to oral mesalazine may improve short-term symptom relief and mucosal healing for left-sided disease, but decisions should be made with your treating clinician based on individual factors and guideline recommendations.
This is a single-center retrospective study with 30-day follow-up; outcomes are short-term and may not predict long-term remission or safety. The study used local modified criteria alongside Mayo components; larger randomized trials are needed.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Mesalamine can rarely cause myocarditis, creating a challenge for ongoing UC treatment. This report shows upadacitinib was used successfully as an alternative when biologics were considered higher cardiac risk and...
Older adults with ulcerative colitis can rarely develop large-vessel giant cell arteritis as an extraintestinal complication.
Higher, optimised doses of prolonged-release mesalazine were linked with fewer clinical recurrences over 12 months in adults with mild-to-moderate UC, which could influence treatment decisions about mesalazine dose and...
